Biotech Values

[dewophile]

JNJ drops RSV vaccine

https://www.reuters.com/business/healthcare-pharmaceuticals/jj-bows-out-rsv-vaccine-race-after-scrapping-trial-2023-03-29/

J&J made the decision in order to "to focus on medicines with the greatest potential benefit to patients," the company said in a statement on Wednesday.

This seems premature to me if it truly is based on the competitive landscape. Why not wait to at least see what the other companies labels look like? JNJ did have 80% efficacy in phase 2 so on par w some of the other RSV players if they could duplicate that in Phase 3
JNJ also recently bowed out of hep B development. A JNJ buyout of GSK now makes sense IMO